OGN NYSE
Organon & Co.
1W: +0.1%
1M: +0.2%
3M: +1.8%
YTD: +90.6%
1Y: +52.4%
3Y: -4.7%
5Y: -52.1%
$13.75
+0.01 (+0.07%)
After Hours: $13.77 (+0.02, +0.11%)
Weekly Expected Move ±0.5%
$14
$14
$14
$14
$14
Credit Risk of going bust: higher than 87% of companies Debt: 70.3% of company value Bonds: $567.6M held by 309 funds, 116 bp over Treasuries → details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $2.25 (down 84%), Organon & Co. would be worth roughly what it owes.
Total debt $8.55B against a stock market value of $3.61B.
Distance to default 1.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.31B (short-term plus half of long-term), stock volatility 62.3%; Altman Z 1.25. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $2.25 (down 84%), Organon & Co. would be worth roughly what it owes.
Total debt $8.55B against a stock market value of $3.61B.
Distance to default 1.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.31B (short-term plus half of long-term), stock volatility 62.3%; Altman Z 1.25. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships3
As Filer
counterparties named
2
As Counterparty
mentioned by others
2
Rel. Types
2021-06-03
Earliest Filing
2024-09-23
Latest Filing
partner: 2
target: 1
Counterparties (Filed by OGN)
3 relationshipsCompanies named in OGN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Dermavant Sciences Ltd. | — | target | Target company in the acquisition agreement with Organon & Co. | 2024-09-23 | View |
| Roivant Sciences Ltd. | ROIV | partner | Representative of Dermavant securityholders in the Merger Agreement. | 2024-09-23 | View |
| Merck & Co., Inc. | MRK | partner | Partner in separation and distribution agreement; spin-off of women's health and biosimilars business. | 2021-06-03 | View |
Mentioned As Counterparty
2 mentionsOther companies that named OGN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ROIV Roivant Sciences Ltd. | target | Acquiring company in a merger agreement with Dermavant. | 2024-09-23 | View |
| MRK Merck & Co., Inc. | acquirer | Separation of women's health, biosimilars and established brands businesses into a separate publicly-traded company | 2021-06-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-31 | Regulation FD; Exhibits | View | |
| 2026-07-23 | Shareholder Vote | View | |
| 2026-07-17 | Other Events | View | |
| 2026-06-11 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-04-27 | Material Agreement; Officer/Director Change; Regulation FD; Exhibits | Agreement | View |
| 2026-02-20 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-07 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-10-27 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-12 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-27 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-04-15 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure | View | |
| 2025-02-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-01-21 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-12-23 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR